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Abstract
Background: We analyzed the association between 53 genes related to DNA repair and p53-mediated damage response
and serous ovarian cancer risk using case-control data from the North Carolina Ovarian Cancer Study (NCOCS), a population-
based, case-control study.
Methods/Principal Findings: The analysis was restricted to 364 invasive serous ovarian cancer cases and 761 controls of
white, non-Hispanic race. Statistical analysis was two staged: a screen using marginal Bayes factors (BFs) for 484 SNPs and a
modeling stage in which we calculated multivariate adjusted posterior probabilities of association for 77 SNPs that passed
the screen. These probabilities were conditional on subject age at diagnosis/interview, batch, a DNA quality metric and
genotypes of other SNPs and allowed for uncertainty in the genetic parameterizations of the SNPs and number of
associated SNPs. Six SNPs had Bayes factors greater than 10 in favor of an association with invasive serous ovarian cancer.
These included rs5762746 (median OR(odds ratio)per allele=0.66; 95% credible interval (CI)=0.44–1.00) and rs6005835
(median ORper allele =0.69; 95% CI =0.53–0.91)i nCHEK2, rs2078486 (median ORper allele =1.65; 95% CI=1.21–2.25) and
rs12951053 (median ORper allele =1.65; 95% CI=1.20–2.26) in TP53, rs411697 (median OR rare homozygote =0.53; 95% CI =0.35
– 0.79) in BACH1 and rs10131 (median OR rare homozygote = not estimable) in LIG4. The six most highly associated SNPs are
either predicted to be functionally significant or are in LD with such a variant. The variants in TP53 were confirmed to be
associated in a large follow-up study.
Conclusions/Significance: Based on our findings, further follow-up of the DNA repair and response pathways in a larger
dataset is warranted to confirm these results.
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Introduction
Ovarian cancer is the leading cause of mortality among
gynecologic cancers [1]. The highly lethal serous histological type
comprises about two-thirds of cases and causes most disease-
related deaths. Reproductive factors such as high parity, oral
contraceptive use, breast feeding, hysterectomy, and tubal ligation
protect against ovarian cancer [2], whereas infertility and
endometriosis increase risk [3,4]. The biological mechanisms that
underlie these risk factors are not well understood, but
inflammation-related oxidative stress has been proposed as a
unifying theory by which these risk factors could cause genomic
damage leading to the development of cancer [5,6,7,8,9]. If this
theory is correct, it is plausible that the risk of ovarian cancer
would be modified by common genetic variants that affect the
efficacy of DNA repair genes [10,11].
Several lines of evidence suggest that DNA repair pathways play
an important role in ovarian carcinogenesis. First, all of the high
penetrance ovarian cancer susceptibility genes that have been
identified thus far play a role in DNA repair. In this regard,
deleterious mutations in the BRCA1 and BRCA2 genes reduce
repair of double stranded DNA breaks. In addition, the germline
mutations in DNA mismatch repair genes that cause Hereditary
Nonpolyposis Colon Cancer (HNPCC) syndrome also strikingly
increase ovarian cancer risk [12,13]. Second, somatic mutations in
the TP53 gene are the most commonly acquired molecular
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[14,15,16]. TP53 is involved in maintenance of genomic integrity
via several mechanisms including induction of cell cycle arrest in
response to DNA damage, DNA repair and regulation of
apoptosis.
The above observations led us to hypothesize that common
polymorphisms in genes associated with DNA response and repair
or the p53-DNA damage checkpoint might increase ovarian
cancer risk. We focused on 477 tagging single nucleotide
polymorphisms (SNPs) and seven additional amino acid changing
SNPs in 53 genes in DNA damage response and repair pathways.
We used a Bayesian model search strategy called Multi-level
Inference for SNP Association (MISA) [17] to analyze these SNPs
for evidence of association with ovarian cancer using data from the
population-based North Carolina Ovarian Cancer Study
(NCOCS).
Bayesian methods are becoming a far more common choice for
analysis of genetic association studies ([18] and references therein).
This can be attributed to several factors including several key
advantages the Bayesian paradigm has over the frequentist
paradigm and to the increasing availability of software specifically
designed for Bayesian analysis of genetic association data such as
the MISA package employed here. The key shortcoming to testing
in the frequentist paradigm is in its failure to explicitly account for
the likelihood of the association arising under the alternative
hypothesis, i.e. to account for power – data that generate a small
p-value under the null may also be very unlikely under the
alternate hypothesis [18]. In contrast, Bayesian methods provide
measures of association – Bayes factors (BFs) and posterior
probabilities – that explicitly account for the likelihood of the data
under the competing hypotheses. This comes at the cost of
additional modeling assumptions; namely, specification of prior
probabilities for each hypothesis and prior distributions over
model parameters conditional on the hypotheses.
MISA [17] improves upon SNP-at-a-time (marginal) methods
by modeling phenotype as a function of a multivariate genetic
profile and, as a result, provides measures of association adjusted
for the remaining markers. MISA employs Bayesian Model
Averaging [19], [20] to account for uncertainty in the specification
of the true model of association, something that stepwise logistic
regression and other model selection approaches such as lasso do
not do. This has important implications: methods that identify a
single model may miss important SNPs due to LD structure. In
addition, MISA provides summaries of the degree to which the
data support an association at the level of individual variants,
genes and pathways while allowing for inference regarding the
genetic parameterization (log-additive, dominant or recessive) of
each SNP. The prior distribution employed by MISA was carefully
chosen for the multiplicity correction it induces.
Materials and Methods
Study subjects
Cases and controls were participants in the NCOCS, conducted
in a 48-county region of North Carolina. A detailed description of
the study has been published previously [2,21]. Briefly, cases were
identified through the North Carolina Central Cancer Registry
using rapid case ascertainment. Eligible cases, aged 20 to 74, were
diagnosed with epithelial ovarian cancer between 1999 and 2007.
Histologic slides were obtained and all cases underwent standard-
ized histopathologic review by the study pathologist (RCB) to
confirm diagnosis. The response rate among eligible cases was
70%. We found little difference in demographic and clinical
characteristics among cases who participated in this study
compared to those who declined. Control women were identified
from the same region using random digit dialing and were
frequency matched to cases by age (five-year categories) and race
(black or non-black). Seventy-three percent of potential controls
who passed the eligibility screening agreed to be sent additional
study information. Among those sent study information, the
response rate was 64 percent. Although the control response rate is
somewhat low, this has not affected associations with established
epidemiological risk factors [2,21]. Additionally, it is unlikely that
participation would have been influenced by genotype. The
protocol was approved by the Duke University Medical Center
Institutional Review Board and the human subjects committees at
the Central Cancer Registry and each hospital where cases were
identified.
We restricted the current analyses to white, non-Hispanic
invasive serous ovarian cancer cases (n=364) and white non-
Hispanic controls (n=761) with genotype data meeting quality
control requirements. Participants had blood drawn during their
in-person interview by the study nurse. Germline DNA was
extracted from peripheral blood lymphocytes using PureGene
DNA isolation reagents, according to manufacturer’s instructions
(Gentra Systems, Minneapolis, MN).
Genotyping Methods
We selected a broad group of candidate genes in the DNA
repair and response pathways (Table S1) that likely interact with
BRCA1 or BRCA2 or are involved in double strand break,
mismatch repair, nucleotide excision repair, or base excision
repair. We tagged these 53 candidate genes using release 19 of the
International HapMap Project’s (www.hapmap.org)[22] CEU
founder population and the ldSelect program [23]. We tagged
the region beginning 10,000 base pairs upstream and ending
10,000 base pairs downstream of each gene so as to include the
coding, non-coding and regulatory regions. ldSelect identified bins
of SNPs with minor allele frequency (MAF) $0.05 using a pair-
wise linkage disequilibrium (LD) threshold of r
2$0.8. We chose to
genotype two tags in bins where all SNPs had low Illumina design
scores to improve expected coverage. For purposes of analysis, we
retained the tag with the more accurate genotype calls as
measured by call frequency and concordance rate in the CEPH
trios. Of the 671 tagging SNPs genotyped, 61 were nonsynon-
ymous; an additional 14 non-tagging amino acid changing SNPs
were also genotyped when the tag that was chosen was also
nonsynonymous. All nonsynonymous SNPs that met the criteria
for the Illumina Golden Gate assays were included. The samples
were genotyped using an Illumina Golden Gate Assay
TM at the
Duke Institute for Genome Sciences and Policy (IGSP), with cases
and controls randomly mixed on each of 21 plates. Six CEPH-
Utah trios (Coriell Institute, Camden, N.J.) were distributed across
six plates. The plates were processed in four batches by the
genotyping facility. SNPs that could not be called using the
Illumina BeadStudio software on more than 1% of samples within
a batch were treated as missing for that batch. We used logistic
regression analysis to determine if batch and DNA quality metrics
were associated with case-control status.
We evaluated the accuracy of the genetic data using SNP- and
subject-specific quality control analyses. First, we removed from all
association analyses SNPs with one or more CEPH genotypes in
disagreement with their published values, i.e. those that had an
estimated error rate greater than or equal to 1/18 assuming the
published genotypes are correct. Second, we utilized the X2
goodness of fit test with continuity correction 0.25 to test for
departures from Hardy-Weinberg-Equilibrium (HWE) among
controls [24] and among the 60 CEPH parents using their
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samples on the basis of an analysis of the left tail of the distribution
of p-values for HWE. This subset accounted for the Illumina
GenCall 50th percentile score (GC50PCT) of each sample and
used the corresponding distribution estimated from the HapMap
CEPH samples for comparison. Reported estimates of minor allele
frequency (MAF) are the minimum of the observed allele
frequencies among controls.
Twenty-two of the 685 DNA repair SNPs on the assay had call
rates below 99% on all four batches and were removed from
further consideration. Thirty-seven of the remaining 663 SNPs
had less than 95% concordance in the CEPH samples between our
genotype calls and those published by HapMap and were removed
from further consideration. Of those remaining, 484 were non-
redundant and included in all subsequent analyses. A QQ plot of
the HWE p-value distribution over these SNPs using all 787 white
non-Hispanic controls showed evidence of an overabundance of
small p-values relative to what is expected under the uniform
distribution. The corresponding plot based on the HapMap
genotypes of the 60 CEPH parents did not have this property.
The number of SNPs with a HWE p-value less than 0.01
calculated using all 787 white non-Hispanic controls was 17; using
the HapMap sample, it was 5. Assuming the p-values are
independent and uniformly distributed the expected number less
than 0.01 is 4.84, the 2.5
th percentile of this distribution is 1 and
the 97.5
th percentile is 10.
This suggests that, rather than having a population genetic
explanation, this departure is likely due to genotyping errors. To
verify this, we considered removing samples with an Illumina
GC50PCT less than a threshold larger than the customary 0.7. We
systematically increased the threshold up to 0.8 and found that the
distribution of HWE p-values was dramatically improved at a
threshold of 0.789. This choice left 364 (of 390) cases and 761
controls. Using this threshold, there were 9 SNPs with a HWE p-
value less than 0.01. All further analyses were conducted using
these samples and their genotype data on the 484 non-redundant
SNPs passing our quality control analysis.
Statistical Methods
MISA Analysis. We used MISA to identify likely associations
and the genetic parameterizations of associated SNPs. MISA
implements a model search over logistic regression models for
case-control status given the SNP variables and a set of design and
potential confounding variables. In the current analyses, age at
diagnosis/interview, batch, the DNA quality metric GC50PCT,
and interaction terms between batch and GC50PCT are the
‘design’ variables included in all models. We refer to the model
with only the design variables as the model of ‘no genetic
association,’ or ‘null’ model for short. It is
logit PD i ~1jZi,M~0 ðÞ ðÞ ~a0zZi 0b0
where Di is the indicator of whether subject i is a case, M is a
model identifier, a0 is the intercept, Zi is the vector of design
variables for subject i, and b0 is the vector of coefficients of the
variables in Zi under the null model. Adding main effects for any
combination of the SNPs to the null model will define a model of
association. MISA allows each included SNP to have a log-
additive, dominant or recessive parameterization. MISA uses an
evolutionary Monte Carlo algorithm to sample models in this class
according to their posterior probabilities. This stochastic search is
carried out in lieu of an enumeration of the models on account of
their huge number.
Because of the astronomical number of statistical models of the
above form, MISA incorporates a permissive single SNP-at-a-time
(marginal) Bayes Factor (BF) screen using the entire set of non-
redundant SNPs to eliminate SNPs unlikely to be associated in the
multivariate logistic regression model. Wilson et al. [17] show that
the screen followed by the multivariate adjusted analysis from
MISA provides increased power to detect associations over the
marginal analysis alone, with minimal increase in false positive
rates. They show that MISA also has much better power than
standard multiple comparison adjustment methods and false
discovery rate procedures, stepwise logistic regression or the lasso.
MISA utilizes a prior distribution over model parameters
calibrated for small to modest effect sizes and a beta-binomial
prior distribution on the number of SNPs included in a model. The
latter distribution induces a multiplicity correction by specifying a
global prior odds of association that is independent of the number
of SNPs or genes in the analysis. Its parameters, a =1/8 and b=S
(the number of SNPs in the model search phase), were chosen on
basis of the results of a simulation experiment to achieve a desired
balance between false positive and false negative rates. More detail
on the statistical methods employed in this analysis can be found in
Wilson et al. [17] (Text S1).
Bayesian Inference. Both the marginal and multivariate
analyses use Bayes factors (BFs) to measure evidence in favor (or
against) an association. The BF is equivalently a generalized
likelihood ratio and an odds ratio. In the former characterization it
is the ratio of the likelihood of the data under one model (e.g. a
model of genetic association) to another (e.g. a model of no genetic
association). Instead of taking the ratio of sampling models under
each hypothesis evaluated at the most likely parameter value
(MLE) of each as in the Frequentist paradigm, the BF is the ratio
of the sampling models averaged over their respective prior
distributions on the model parameters. In the latter
characterization, BFs are defined as the ratio of the posterior
odds of a hypothesis (or model) of association to the prior odds (p/
(1- p)) of that hypothesis and, hence, measure the degree to which
the data update the odds of that hypothesis of association
[25,26,27]; with a BF of 10, the posterior odds of an association
are 10 times larger than the prior odds. Under a commonly used
scale of evidence [28], BFs between 1.0 and 3.2 are ‘weakly
supportive’, those between 3.2 and 10 are ‘supportive’, those
between 10 and 30 are ‘strongly supportive’, those between 30 and
100 are ‘very strong’ and those above 100 are ‘decisive’ for support
of association (we have changed the names of several of these
categories, but not their interpretation). A BF for no association is
simply the reciprocal of the BF for an association, thus unlike p-
values BFs can provide a measure of support in favor of a null
hypothesis. BFs may be converted to posterior odds (PO = BF x
p/(1- p)), and to posterior probabilities of association (PPA = PO/
(1+ PO)) to provide an ‘‘absolute’’ measure of evidence of
association[18]. The posterior probabilities may be used as part of
a decision analysis to determine which SNPs to pursue further. A
threshold of 0.5 for the PPA, assumes that false positives have the
same cost as false negatives. For preliminary studies, a lower
threshold may be more appropriate.
Missing Data. There were no missing design variables. We
used fastPHASE [26] to generate 100 imputations of the missing
genotype data given the observed, unphased genotype data. The
screen’s marginal BFs were calculated as the simple average of the
BFs for each of the 100 imputed data sets. We compared these BFs
to those calculated with a single data set in which the missing
genotypes were replaced by their modal value determined from
the 100 imputations. The two sets of BFs had correlation 0.998.
For this reason and because computations are greatly streamlined,
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analysis.
Our imputation procedure assumes that missing SNP genotypes
are ignorable, i.e. either missing completely at random (MCAR) or
missing at random (MAR). We used the marginal BF software to
check this assumption by investigating whether a SNP’s pattern of
missingness was conditionally independent of case-control status
given the observed data we have for explaining missingness. The
design variables in this analysis were the same as used in the screen
and in MISA. For purposes of this calculation, we used the 0–1
indicator for a SNPs missingness in place of its genotype data and
calculated BFs for association of this indicator to case-control
status under the log-additive model for SNPs with five or more
missing values (60 SNPs).
Design Variables. Logistic regression analysis of case-control
status on batch and GC50PCT indicated a strong batch effect
(p,10e
27), largely driven by an uneven allocation of cases and
controls in batch four and a batch-GC50PCT interaction
(p=0.02). On the basis of this analysis, we include batch,
GC50PCT, the interaction between batch and GC50PCT in all
association models along with age.
Haplotype Analysis. Associations with one or more SNPs in
a gene may occur when those variants tag a risk haplotype. We
used Haploview 4.1 to carry out haplotype association tests to
ascertain whether this might be the case in the genes containing
the most highly associated SNPs.
Results
NCOCS Candidate DNA Repair Gene Analysis
In the marginal SNP-at-a-time analysis of the 484 non-
redundant SNPs passing quality control, S=77 SNPs passed the
marginal screen (maximum marginal BF .1.0). (The results of the
screening phase of analysis, including median odd ratios (ORs),
95% credible intervals (CIs) and MAFs for all 484 SNPs are shown
in Table S2.) We ran MISA using the 77 SNPs that passed the
screen with parameters a=1/8 and S=77, which leads to marginal
prior odds of association in this subset of 1/axS =0.0016. Table 1
lists the SNP-specific BFs for the 41 SNPs in 25 genes that had a
MISA BF .1.0. The table also reports the most likely genetic
model for each SNP, the posterior probability of that model and
median ORs and 95% CI estimates.
Of these 41 SNPs, six SNPs in four genes (CHEK2, TP53,
BACH1 and LIG4) have MISA BF .10 providing evidence for an
association between these SNPs and ovarian cancer. These are
rs5762746 (BF=28.940) and rs6005835 (BF=28.028) in CHEK2,
rs2078486 (BF=19.604) and rs12951053 (BF=14.062) in TP53,
rs411697 (BF=15.909) in BACH1 and rs10131 (BF=10.864) in
LIG4. Fourteen SNPs in seven genes including GADD45B, MSH3,
MSH6, NBS1, RAD52, TP53, and XRCC5 had BFs ranging from
3.39–9.09, with posterior odds that are 3.39 to 9.09 times larger
than the prior odds. The SNP-specific Bayes Factors are composite
measures that average over statistical models of association that
include that SNP while adjusting for other potentially associated
SNPs and their genetic parameterizations. Hence, they explicitly
account for uncertainty in the specification of the statistical model
of association.
Figure 1 summarizes the associations of the 20 SNPs with MISA
BF.3.2. This plot summarizes the top 100 models selected on the
basis of their posterior model probabilities. Models are ordered on
the x-axis in descending probability and the width of the column
associated with a model is proportional to that probability. SNPs
are represented on the y-axis. Presence of a SNP in a model is
indicated by a colored block at the intersection of the model’s
column and the SNP’s row. The color of the block indicates the
genetic parameterization of the SNP in the given model: purple for
log-additive, blue for recessive and red for dominant. A
checkerboard pattern as opposed to a pattern of strong vertical
bands indicates substantial model uncertainty. Seventy-eight of the
top 100 models depicted in Figure 1, including the top 48 models,
include only a single SNP in addition to the design variables. Only
22 of the top 100 models included two SNPs and none of them
included more than two. The top model includes only the log-
additive genetic parameterization of rs6005835 in CHEK2 with a
Maximum A Priori (MAP) estimate of the OR of 0.70. The second
ranked sampled model is comprised of the log-additive genetic
parameterization of rs5762746 in CHEK2 with a MAP OR of
0.73. SNPs rs6005835 and rs5762746 in CHEK2 have a modest
LD, measured as r
2 of 0.5.
Models that incorporate multiple SNPs represent 22 of the top
100 models by number, but only 7.8% of their total posterior
mass. The low relative weighting of this class of models is largely a
result of the strong MISA multiplicity correction that controls the
false positive rate associated with calls made on the basis of SNP-
specific BFs. The highest ranked multi-SNP model (rank=49)
includes CHEK2 rs5762746 and TP53 rs2078486. These variants
are complementary predictors, each explaining as much variability
in case-control status when modeled alone as when modeled in the
presence of the other. This suggests that SNPs from multiple genes
related to DNA damage repair provide complementary informa-
tion for characterizing ovarian cancer risk.
Haplotype Analysis.. A Haploview [29] analysis of CHEK2,
TP53, BACH1 and LIG4, containing the top six SNPs, showed no
evidence for multi-SNP (haplotype-based) risk genotypes.
Analysis of missing data. Of the 60 SNPs with more than 4
missing SNP genotypes, only six had BFs.1.0 for conditional
dependence of case-control status on missingness given the design
variables. Four of these BFs were in the range from 1.01 to 1.49
and are not of concern. The remaining two, rs11571789 in
BRCA2 (BF=3.80) and rs1805794 in NBS1 (BF=4.60), were
‘supportive’ of association. These may be due either to chance or
to the presence of an unmeasured confounder and reflect a pattern
of non-ignorable missingness. Missing data imputations that ignore
the possibility of low frequency polymorphisms which interfere
with the ability to assay a probe will not account for the LD
between the rare associated variant and the SNP with missing
values. The ultimate effect when fitting the association models for
this SNP will be for the SNPs apparent effect to be biased. BRCA2
rs11571789’s maximum marginal BF for association with ovarian
cancer was 0.26 (‘supportive’ of no association) and was not
included in the MISA analysis. NBS1 rs1805794’s maximum
marginal BF was 1.76 and its MISA BF was 3.82. This modest
evidence in favor of association should be interpreted in light of
the potential for this effect to have been confounded.
Discussion
The results of this study provide evidence for an association
between several genes in the DNA repair and response pathways
and risk of invasive serous ovarian cancer. There was strong
support for associations between ovarian cancer and two SNPs in
CHEK2, two SNPs in TP53, and one SNP each in BACH1, and
LIG4. Our analyses are also supportive of associations between
four SNPs in NBS1, three SNPs in MSH3, three SNPs in RAD52,
and one SNP each in GADD45B, MSH6, TP53, and XRCC5 and
invasive serous ovarian cancer. To our knowledge, this is the first
study suggesting associations between ovarian cancer and SNPs in
CHEK2, BACH1, XRCC5, NBS1, MSH6, RAD52, and GADD45B.
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Most Likely Model
SNP Gene Model Probability Median OR (95% CI)
* BF
BFs are strongly supportive of an association
rs5762746 CHEK2 Log Additive 0.643 0.66 (0.44, 1.00) 28.940
rs6005835 CHEK2 Log Additive 0.752 0.69 (0.53, 0.91) 28.028
rs2078486 TP53 Log Additive 0.653 1.65 (1.21, 2.25) 19.604
rs411697 BACH1 Recessive 0.988 0.53 (0.35, 0.79) 15.909
rs12951053 TP53 Log Additive 0.618 1.65 (1.20. 2.26) 14.062
rs10131 LIG4 Recessive 0.988 NA
{ 10.864
BFs are supportive of an association
rs2287497 TP53 Log Additive 0.623 1.50 (1.14, 1.96) 9.086
rs11571424 RAD52 Recessive 0.962 7.55 (1.70, 33.47) 8.388
rs3732191 MSH6 Recessive 0.428 NA 7.589
rs16855489 XRCC5 Dominant 0.963 0.69 (0.54, 0.88) 7.353
rs32989 MSH3 Dominant 0.675 0.73 (0.57, 0.93) 6.527
rs6470522 NBS1 Recessive 0.48 1.91 (0.77, 4.75) 5.712
rs245346 MSH3 Log Additive 0.608 0.76 (0.61, 0.95) 5.493
rs929461 GADD45B Recessive 0.932 NA 4.933
rs7307680 RAD52 Dominant 0.804 0.72 (0.55, 0.94) 4.796
rs4703819 MSH3 Recessive 0.963 NA 4.422
rs1805794
{ NBS1 Recessive 0.471 0.67 (0.42, 1.07) 3.823
rs1063045
{ NBS1 Recessive 0.557 0.66 (0.41, 1.07) 3.682
rs11571461 RAD52 Recessive 0.875 NA 3.484
rs1061302
{ NBS1 Recessive 0.55 0.66 (0.40, 1.07) 3.388
BFs are weakly supportive of an association
rs1981929 MSH2 Dominant 0.900 1.40 (1.09, 1.80) 3.116
rs7546055 GADD45A Dominant 0.709 1.32 (1.04, 1.68) 2.687
rs2832283 BACH1 Log Additive 0.586 0.70 (0.42, 1.17) 2.468
rs6151640 MSH3 Recessive 0.950 0.14 (0.02, 0.97) 2.381
rs4150383 ERCC5 Dominant 0.710 0.74 (0.58, 0.96) 2.289
rs175057 MLH3 Dominant 0.849 1.41 (1.07, 1.87) 2.169
rs2299612 FANCG Dominant 0.847 1.37 (1.07, 1.74) 2.046
rs1011980 XRCC4 Recessive 0.938 0.48 (0.27, 0.86) 2.000
rs1498313 MSH4 Dominant 0.766 1.33 (1.02, 1.73) 1.952
rs7735781 XRCC4 Recessive 0.906 NA 1.893
rs3093933 PARP2 Recessive 0.667 0.63 (0.36, 1.11) 1.826
rs7190823
{ FANCA Recessive 0.875 1.48 (1.09, 2.00) 1.699
rs3780560 FANCC Recessive 0.784 NA 1.588
rs1233276 PMS1 Recessive 0.693 1.83 (1.08, 3.10) 1.460
rs2678681 PARP2 Recessive 0.799 NA 1.456
rs13292454 FANCC Log Additive 0.463 2.11 (0.58, 7.68) 1.418
rs709816
{ NBS1 Recessive 0.723 0.65 (0.44, 0.95) 1.360
rs4253211
{ ERCC6 Log Additive 0.406 0.45 (0.11, 1.88) 1.326
rs1006548 FANCA Recessive 0.918 1.91 (1.12, 3.25) 1.239
rs5030783 RAD51 Recessive 0.893 0.64 (0.43, 0.95) 1.236
rs769412
{ MDM2 Log Additive 0.438 1.40 (1.00, 1.96) 1.073
Abbreviations: MISA, Multilevel Inference for SNP Association Studies; SNP, single nucleotide polymorphism; BF, Bayes factor; OR, odds ratio; CI, credible interval.
*The OR corresponds to the posterior mode (equivalent to the maximum likelihood estimate (MLE)) under the normal prior distribution with mean equal to the MLE on
coefficients implied by AIC under the most likely genetic model identified by MISA. The 95% CI is the 95% equal tailed posterior credible interval under the normal
prior.
{The maximum likelihood estimate does not exist.
{Indicates the SNP is a nonsynonymous coding SNP (i.e., amino acid changing).
doi:10.1371/journal.pone.0010061.t001
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highly associated SNPs may have functional significance.
We used SNPInfo analysis [30] to determine if any of the six
SNPs with a MISA BF .10 were in LD with a putative functional
variant or are predicted to have functional significance. We
examined each HapMap SNP with LD of 0.5 or higher to one of
the six top SNPs. Table S3 reports whether the variant is predicted
to affect a transcription factor binding site, a splicing site, an
miRNA binding site or alter the structure of a protein product. In
addition, it indicates whether the SNP is a non-synonymous or
nonsense variant and reports its regulatory potential and sequence
conservation scores. Based on this analysis, both rs10131 in LIG4
and rs9587535 in ABHD13, a SNP in high LD with rs10131
(LD=0822) are predicted by miRanda [31] to affect an miRNA
binding site. In addition, rs10131 has a high predicted sequence
conservation score (for a non-coding variant). Two other LIG4 LD
SNPs (rs1931336 and rs9587535 with LD 0.59 and 0.82 with
rs10131, respectively) also have this property. Several variants in
weak LD (0.5,LD,0.7) with TP53 rs12951053 are predicted to
affect a transcription factor binding site; one of these (rs17882227)
is in perfect LD with TP53 rs2078486, one of the most highly
associated SNPs. In addition, rs2287498 in WDR79 (in perfect LD
with rs2078486 and in LD (R
2=0.62) with rs12951053) is
predicted to affect function at a splice site and a non-synonymous
variant (rs2287499) in WDR79 in weak LD with the two most
highly associated TP53 SNPs is predicted by PolyPhen [32] to be
benign. Several of the non-coding TP53 variants have high
regulatory potential and/or sequence conservation scores; of these
rs17882227 is in highest LD (1.0) with a top candidate
(rs2078486). SNP rs388707 in LD with BACH1 rs411697 is
predicted to affect splicing, while another SNP (rs425989) in LD
with rs411697 is predicted by miRanda to affect an miRNA
Figure 1. Models are ordered on the x-axis in descending posterior probability with the width of the column associated with a
model proportional to the model’s posterior probability. Individual SNPs are represented on the y-axis with labels giving the gene and RS
number for the SNP and are ordered on the basis of the Bayes Factor in favor of SNP association, which are given on the y-axis on the right side of the
plot. The presence of a SNP in a model is indicated by a colored block at the intersection of the model’s column and the SNP’s row, while the color of
the block indicates the parameterization of the SNP: purple for log-additive, blue for recessive and red for dominant.
doi:10.1371/journal.pone.0010061.g001
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BACH1 candidate have sequence conservation scores greater than
0.1, suggesting that they may be functionally interesting. Several
variants in and near CHEK2 demonstrate the potential to affect
function. There are a number of non-coding CHEK2 SNPs (e.g.
rs5762629, rs2346397 and the top SNP rs6005835) with high
regulatory potential or sequence conservation scores. In addition
to having a high regulatory potential score, SNP rs6005835 in
CHEK2 is predicted to affect a transcription factor binding site.
In addition to the functional significance, a recently published
multi-center study [33] (which included data from the NCOCS)
examined six SNPs in TP53 and validated our findings (with and
Table 2. Comparison of SNPs with MISA Bayes Factors .1.0 to previously published data.
*
Gene
Associated
SNP(s) from
NCOCS
MISA BF for associated
SNP(s) from NCOCS
SNPs examined
in previous studies
Maximum r
2 and/or r
2$0.75
between associated NCOCS
SNP and SNP from previous study
TP53 rs2078486
rs12951053
rs2287497
19.604
14.062
9.086
rs2078486[33]
{
rs12951053[33]
{
rs2287497[33]
{
1.00 (rs2078486, rs2078486)
1.00 (rs12951053, rs12951053)
1.00 (rs2287497, rs2287497)
NBS1 rs6470522 rs1805794
rs1063045 rs1061302
rs709816
5.712
3.823
3.682
3.388
1.360
rs1805794[34]
rs1063045[34]
rs1061302[34]
rs709816[34]
1.00 (rs1805794, rs1805794)
1.00 (rs1061302, rs1061302)
1.00 (rs1063045, rs1063045)
1.00 (rs709816, rs709816)
LIG4 rs10131 10.864 rs1805386[37] 0.02 (rs10131, rs1805386)
MLH3 rs175057 2.169 rs7303[35]
rs175080[35]
0.93 (rs175057, rs175080)
0.78 (rs175057, rs7303)
MSH2 rs1981929 3.116 rs4952887[35]
{
rs2303428[35]
{
rs1981928[35]
rs2059520[35]
rs3771274[35]
rs3771281[35]
rs13425206[35]
0.44 (rs1981929, rs3771274)
MSH3 rs32989
rs245346
rs4703819
rs6151640
6.527
5.493
4.422
2.831
rs26279[35]
rs10079641[35]
rs6151662[35]
{
rs26282[35]
rs26779[35]
rs33008[35]
rs40139[35]
rs184967[35]
rs2112416[35]
rs2897298[35]
1.00 (rs32989, rs26279)
1.00 (rs6151640, rs10079641)
MSH6 rs3732191 7.589 rs2348244[35]
rs3136245[35]
{
rs1800932[35]
rs1800935[35]
rs3136272[35]
rs3136317[35]
rs2020911[35]
0.40 (rs3732191, rs2348244)
PMS1 rs1233276 1.460 rs3762545[35]
rs5742981[35]
rs5741593[35]
rs1233291[35]
rs1233255[35]
rs1233258[35]
rs256571[35]
rs256563[35]
0.85 (rs233275, rs1233255)
RAD52 rs11571424
rs7307680
rs11571461
8.388
4.796
3.484
rs11226[34]
rs4987208[38]
0.06 (rs11571461, rs11226)
RAD51 rs5030783 1.236 rs1801320[34]
rs1801321[34]
0.48 (rs5030783, rs1801321)
Abbreviations: NCOCS, North Carolina Ovarian Cancer Study; SNP, single nucleotide polymorphism; BF, Bayes factor; MISA, Multilevel Inference for SNP Associations.
NOTE: SNPs in bold font are common to both the current NCOCS study and to previously reported studies.
*Previous reports include: Multiple reports from the same study;[34,35,36] one report that used data from two related case-control studies in Australia;[38] one Ovarian
Cancer Association Consortium (OCAC) meta-analysis[37] that includes overlap of data from the Auranen et al.[34] and Beesley et al.[38] studies; and one OCAC analysis
that includes data from the current NCOCS study[33].
{SNP was statistically significantly associated with ovarian cancer in the previous study.
{The ORs for the heterozygote genotypes, but not the homozygote rare genotypes, were statistically significant. The overall p- trend values were greater than 0.05.
1SNP was statistically significantly associated with ovarian cancer in the Auranen et al.[34] study but not the other two published studies.
doi:10.1371/journal.pone.0010061.t002
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association in our study include two tagging SNPs in TP53,
rs12951053 and rs2287497, both of which were replicated with
posterior median ORs of 1.19 (95% CI: 1.01, 1.38) and 1.30 (95%
CI: 1.07, 1.58), respectively [33]. A third SNP in TP53, rs2078486,
was also associated with ovarian cancer in three independent
datasets in the same report. Although our data support that two
SNPs in the CHEK2 gene are associated with the risk of
developing invasive serous ovarian cancer, it is of note that one
prior study in Poland did not find evidence for an association
between invasive epithelial ovarian cancer of any histologic
subtype and three founder alleles in the CHEK2 gene but did
find evidence for an association with ovarian tumors of low
malignant potential and the CHEK2 I157T missense variant
{Szymanska-Pasternak, 2006 #447}.
Other studies that have assessed associations between variants in
the DNA repair genes included in the current analysis and ovarian
cancer risk [34,35,36,37] are summarized in Table 2. Differences
in the findings between studies when the SNPs were in high LD
may be explained by differences in the analytic approach and the
mode of inheritance analyzed. Our approach included a two-
staged analysis plan that provided increased power to detect SNP
associations and accounted for multiple modes of inheritance. A
strength of the current study was the restriction to invasive serous
ovarian cancers, whereas previous reports often combined
histologic subtypes. By restricting to the serous invasive subtype,
we achieve a more homogenous subset of ovarian cancers likely to
have similar etiology and genetic factors and avoid diluting the
magnitude of associations. In addition, inclusion of prevalent,
rather than only incident, cases may be a source of inconsistency
between studies.
Despite the relatively small sample size (364 cases/761 controls)
our analyses provide supportive evidence for associations with
several candidate genes in the DNA repair and response pathways.
Additionally, we have found evidence to suggest that the six most
highly associated SNPs either may have functional significance or
are in LD with a functional variant. Future work to replicate and
characterize these associations in serous ovarian cancer is needed,
as well as an examination of the three other important histologic
subtypes of invasive ovarian cancer including mucinous, endome-
trioid and clear cell cancers. Because ovarian cancer is a leading
cause of gynecologic cancer morbidity and mortality and DNA
repair and response is a vitally-important pathway, the identifi-
cation of genes and genetic variants in these pathways using a well-
informed selection of SNPs may lead to the identification of genes
for targeted preventive studies.
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